Feature | June 11, 2014

Radioluminescence Tells the Story of Single Cells

SNMMI Radioluminescence Single Cells Nuclear Imaging

June 11, 2014 — With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

A resolution of 20 micrometers or microns — about a quarter of the diameter of a single human hair — is made possible with an imaging technique that unites the physics of nuclear medicine with optical imaging. Researchers inject a radioactive material that acts upon an ultrathin scintillator, which fluoresces when it detects charged particles. The fluorescent signal is then picked up by a specialized radio-luminescence microscope.

“Our research seeks to answer the question: In a population of cells, how important is individuality? Are the cells so similar that just knowing the average of a cell population is sufficient, or is there a need to look at individual cells, one by one?” These are the questions being answered by Guillem Pratx, Ph.D., assistant professor of radiation physics and radiation oncology at Stanford University, Stanford, Calif., and principal investigator of the clinical study.

Imaging the physiological functions of the body is possible with radiotracers, imaging agents that combine a radioactive material and molecular compound that interacts with biochemical processes. For this study, radiotracers interact with live cells viewed by radio-luminescence microscopy. The specialized microscope’s CdWO4 scintillator captures beta particles as they are emitted by the radiotracer in the cell sample. By compiling these atomic events, the scintillator can reconstruct the data into an image that nuclear medicine physicians use to interpret disease pathology and response to drug treatment.

“Our goal is to characterize radiotracers from the perspective of how they interact with single cells,” said Pratx. “The conventional methods used in nuclear medicine use large numbers of cells to produce measurements of cellular characteristics, because they do not have the spatial resolution to see single cells. Very little research, if any, has looked at what happens at the scale of a single cell.”

The innovation of this particular microscope is not only its detector but also to its ability to capture optical brightfield and fluorescence images. The two models differ only by their lens — one includes a commercial grade 0.2X tube lens and the other a custom 1X tube lens.

Researchers used these systems to image how single breast cancer cells used a radiotracer called F-18 fluorodeoxyglucose (F-18 FDG), a molecular compound that mimics glucose as fuel for cellular processes. The breast cells showed unexpected and intense variation. The team also imaged a human antigen called CD20, which can signal cancer of the blood, or lymphoma, on a transplanted sample of small animal spleen tissue, and assessed how the sample responded to a simultaneous radionuclide and antibody lymphoma therapy called Zr-89 Rituximab. The radioluminescence microscope was able to clearly visualize the expression of CD20 from malignant B cells in the spleen sample.

“This new tool will help nuclear medicine and molecular imaging advance toward more personalized radionuclide imaging,” Pratx explained. “Since we are able to see how properties of single cells impact their interaction with radiotracers, there is an opportunity to develop new radiotracers that are biologically optimized to target specific disease pathways.”

Further studies are required to validate the research for radioluminescence microscopy in order to secure regulatory approval for commercial use.

For more information: www.snmmi.org

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...